AIDS vaccine efficacy trials: Expand capacity and prioritize - 'Throughout Africa, Asia and Latin America, state-of-the-art clinics and laboratories...exist where, 4 years ago, there were none'

Expert Review of Vaccines

Volumn 5, Issue 2, 2006, Pages 167-170

  Excler, Jean Louis ^a  

^a INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MICROBICIDE;

CLINICAL TRIAL; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; EDITORIAL; ETHNIC GROUP; FEASIBILITY STUDY; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFECTION RISK; MALARIA; MEDICAL PRACTICE; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; TUBERCULOSIS; VIRUS TRANSMISSION; AFRICA; ASIA; CONTROLLED CLINICAL TRIAL; LABORATORY; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; SOUTH AND CENTRAL AMERICA;

AFRICA; AIDS VACCINES; ASIA; DEVELOPING COUNTRIES; HUMANS; LABORATORIES; LATIN AMERICA; RANDOMIZED CONTROLLED TRIALS;

EID: 33746771454     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.5.2.167     Document Type: Editorial

References (28)

1. UNAIDS. AIDS epidemic update. December 2005.
2. Emini EA, Koff WC. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope. Science 304(5679), 1913-1914 (2004).
3. Esparza J, Osmanov S. HIV vaccines: a global perspective. Curr. Mol. Med. 3(3), 183-193 (2003).
4. Mugerwa RD, Kaleebu P, Mugyenyi P et al. HIV-1 Vaccine Trial Group First trial of the HIV-1 vaccine in Africa: Ugandan experience. Br. Med. J. 324(7331), 226-229 (2002).
5. Excler JL, Beyrer C. Human immunodeficiency virus vaccine development in developing countries. Are efficacy trials feasible? J. Hum. Virol. 3(4), 193-214 (2000).
6. Esparza J, Burke D. Epidemiological considerations in planning HIV preventive vaccine trials. AIDS 15(Suppl. 5), S49-S57 (2001).
7. Brown BK, Darden JM, Tovanabutra S et al. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J. Virol. 79(10), 6089-6101 (2005).
8. Karita E. HIV incidence among discordant couples in Zambia and Rwanda. AIDS Vaccine 2004. Lausanne, Switzerland, 33 (2004).
9. Nyblade LC, Menken J, Wawer MJ et al. Population-based HIV testing and counseling in rural Uganda: participation and risk characteristics. J. Acquir. Immune Defic. Syndr. 28(5), 463-470 (2001).
10. Allen S, Meinzen-Derr J, Kautzman M et al. Sexual behavior of HIV discordant couples after HIV counseling and testing. AIDS 17(5), 733-740 (2003).
11. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Tweedy KG. Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection: a randomized controlled trial. JAMA 287(9), 1117-1122 (2002).
12. Hayes R, Weiss H. Understanding HIV epidemic trends in Africa. Science 311(5761), 620-621 (2006).
13. Kawichai S, Celentano DD, Vongchak T et al. HIV voluntary coubnselling and testing and HIV incidence in male injecting drug users in northern Thailand. J. Acquir. Immune Defic. Syndr. 31(2), 186-193 (2006).
14. Reynolds SJ, Risbud AR, Godbole SV et al. Comparison of risk factors for incident sexually transmitted infections among men attending STI clinics in Pune, India. XV International AIDS Conference. Bangkok, Thailand, ThPpC2097 (2004).
15. Choopanya K, Des Jarlais DC, Vanichseni S et al. HIV risk reduction in a cohort of injecting drug users in Bangkok, Thailand. J. Acquir. Immune Defic. Syndr. 33(1), 88-95 (2003).
16. Vanichseni S, Des Jarlais DC, Choopanya K et al. Sexual risk reduction in a cohort of injecting drug users in Bangkok, Thailand. J. Acquir. Immune Defic. Syndr. 37(1), 170-179 (2004).
17. Brown T, Peerapatanapokin W. The Asian epidemic model: a process model for exploring HIV policy and programme alternatives in Asia. Sex. Transm. Infect. 80(Suppl. I), I19-I24 (2004).
18. Ruxrungtham K, Brown T, Phanuphak P. HIV/AIDS in Asia. Lancet 364(9428), 69-82 (2004).
19. Charles M. HIV epidemic in Cambodia, one of the poorest countries in Southeast Asia: a success story. Expert. Rev. Antiinfect. Ther. 4(1), 1-4 (2006).
20. Caldwell JC, Isaac-Toua G. AIDS in Papua New Guinea: situation in the Pacific. J. Health Popul. Nutr. 20(2), 104-111 (2002).
21. Ruan Y, Qin G, Liu S et al. HIV incidence and factors contributed to retention in a 12-month follow-up study of injection drug users in Sichuan Province, China. J. Acquir. Immune Defic. Syndr. 39(4), 459-463 (2005).
22. Godbole S, Mehendale S. HIV/AIDS epidemic in India: risk factors, risk behaviour and strategies for prevention and control. Indian J. Med. Res. 121(4), 356-368 (2005).
23. van Griensven F, Thanprasertsuk S, Jommaroeng R et al. Evidence of a previously undocumented epidemic of HIV infection among men who have sex with men in Bangkok, Thailand. AIDS 19(5), 521-526 (2005).
24. Jaspan HB, Lawn SD, Safrit JT, Bekker LG. The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents. AIDS 20(4), 483-494 (2006).
25. Luzuriaga K, Newell ML, Dabis F, Excler JL, Sullivan JL. Pediatric preventive HIV/AIDS vaccines: scientific and logistical priorities. Lancet (2006) (In Press).
26. Esparza J. The global HIV vaccine enterprise. Int. Microbiol. 8(2), 93-101 (2005).
27. Rida W, Fast P, Hoff R, Fleming T. Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 16(3), 195-203 (1997).
28. NIAID begins enrolling volunteers for Phase IIB study of Merck's vaccine. IAVI Rep. 9(1), 16 (2004 Dec-2005 Mar).